[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344824-105":59,"doc-detail-344824-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-development-of-antibody-functionalized-liposomes-via-click-chemistry-for-precision-targeting-of-pd-l1-positive-ovarian-cancer","The Development of Antibody-Functionalized Liposomes via Click Chemistry - for Precision Targeting of PD-L1-Positive Ovarian Cancer","","Cancer therapy faces major limitations in conventional chemotherapy, including severe systemic side effects that reduce quality of life and often require dose reductions or interruptions. Nanotechnology-based liposomes offer biocompatible, stable carriers that can be functionalized for targeted drug delivery, yet antibody attachment remains difficult due to unstable binding, improper functionalization, and laborious coupling. This study develops an antibody-functionalized liposomal system covalently conjugated with Atezolizumab to deliver doxorubicin selectively to PD-L1-positive ovarian cancer cells, optimizing size (100–200 nm) and reducing systemic toxicity while enhancing tumor accumulation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-development-of-antibody-functionalized-liposomes-via-click-chemistry-for-precision-targeting-of-pd-l1-positive-ovarian-cancer/344824/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-development-of-antibody-functionalized-liposomes-via-click-chemistry-for-precision-targeting-of-pd-l1-positive-ovarian-cancer/344824.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do chemotherapy treatments create a need for targeted drug delivery?","Question",{"text":112,"@type":113},"Conventional systemic chemotherapy lacks specificity, distributing drugs throughout the body and causing severe side effects. This often forces dose reductions or treatment interruptions, motivating targeted delivery approaches.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What problem does this study address in antibody-functionalized liposome design?",{"text":117,"@type":113},"Attaching targeting antibodies to liposomes can suffer from insufficient or unstable binding, improper functionalization, poor stability, and tedious coupling processes. The study targets these issues by using a covalent conjugation strategy.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the click chemistry approach improve targeting of ovarian cancer cells in this study?",{"text":121,"@type":113},"The study uses covalent conjugation between a modified antibody and functionalized liposomes via click chemistry, forming a targeted nanocarrier. It delivers higher doxorubicin levels to PD-L1-overexpressing SKOV-3 cells with reduced systemic toxicity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344824,1790875965,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","This article is licensed under CC-BY-NC-ND 4.0   \n[http://pubs.acs.org/journal/acsodf](http://pubs.acs.org/journal/acsodf)  Article   \nThe Development of Antibody-Functionalized Liposomes via Click Chemistry for Precision Targeting of PD-L1-Positive Ovarian Cancer  \nBama Prasanna Chatterjee, Malabika Ghosh, Uddipan Dasgupta, Indranil Chatterjee, Somya Agrawal, Sushant Singh, Ankan Dutta Chowdhury, * and Padmalaya Das*  \n Cite This: ACS Omega 2026, 11, 9212−9220  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: Cancer treatment faces significant difficulties with chemotherapy, often leading to severe side effects. This encourages the need for research on innovative, selective therapies for targeted drug delivery, particularly using nanotechnology-based liposomes as carriers. Liposomes, spherical nanocarriers, can encapsulate drugs and be functionalized for targeted delivery, boosting drug accumulation in cancer cells while minimizing harm to healthy tissues. However, to introduce the targeting ability, the attachment of biomarkers with liposomes always faces several challenges such as insufficient and unstable binding, improper functionalization, poor stability, and a tedious attachment process. This study developed an antibodyfunctionalized liposomal system, covalently conjugated with Atezolizumab, a monoclonal antibody against programmed death-ligand 1 (PD-L1) to form antibody-lipid-doxorubicin (AbLip-Dox), a targeted nanocarrier system. Unlike conventional attachment methods, this study employs a covalent conjugation strategy based on click chemistry between a modified antibody and functionalized liposomes, representing the innovation of the work. It selectively delivered higher doxorubicin (Dox) to ovarian cancerous SKOV-3 cells overexpressing PD-L1. The nanocarrier, with an optimized size (100 − 200 nm) and a doxorubicin concentration (1 μg/mL), effectively reduces systemic toxicity and enhances drug accumulation in tumor cells through site-specific delivery. The success of this approach lays the groundwork for the development of next-generation targeted therapies for ovarian and other PD-L1-expressing cancers.  \n1. INTRODUCTION  \nCancer remains one of the most serious global health challenges, defined by unchecked cell growth and metastatic spread, which contribute to high rates of morbidity and mortality worldwide.1 Globally, millions of new cancer cases are diagnosed annually, contributing to a significant economic and social burden.2 The cancer burden is escalating, with a substantial number of people living with the disease and arising incidence of new cases each year, necessitating urgent intervention to restrict projected increases in mortality rates.3 Current conventional cancer treatments, including surgical intervention, radiation therapy, and systemic chemotherapy, have undeniably advanced patient outcomes.4 While these modalities are effective in many instances, they are often associated with significant limitations. Surgery, though curative for localized tumors, can present challenges in advanced or metastatic disease.5 Radiation therapy, effective for both primary and metastatic sites, can cause collateral damage to healthy tissues within the treatment field, leading to various adverse effects.6 However, chemotherapy frequently presents challenging drawbacks.7 Systemic chemotherapy agents, by nature, lack specificity, leading to widespread distribution throughout the body. This nonspecific targeting results in severe systemic side effects, profoundly impacting patients’quality of life and often necessitating dose reductions or  \ntreatment interruptions.7 In response to these challenges, targeted drug delivery systems have emerged as a highly promising avenue in oncology.8 These innovative platforms aim to revolutionize cancer therapy by precisely delivering therapeutic agents to mali","cbCaibP3UCl8NKYw","https://ap.wps.com/l/cbCaibP3UCl8NKYw","pdf",4424965,"English","# ABSTRACT\n## INTRODUCTION\n## Targeted drug delivery and limitations of chemotherapy\n## Liposomes for nanocarrier delivery and PD-L1 as a target\n## Immune checkpoint relevance and rationale for antibody functionalization","[{\"question\":\"Why do chemotherapy treatments create a need for targeted drug delivery?\",\"answer\":\"Conventional systemic chemotherapy lacks specificity, distributing drugs throughout the body and causing severe side effects. This often forces dose reductions or treatment interruptions, motivating targeted delivery approaches.\"},{\"question\":\"What problem does this study address in antibody-functionalized liposome design?\",\"answer\":\"Attaching targeting antibodies to liposomes can suffer from insufficient or unstable binding, improper functionalization, poor stability, and tedious coupling processes. The study targets these issues by using a covalent conjugation strategy.\"},{\"question\":\"How does the click chemistry approach improve targeting of ovarian cancer cells in this study?\",\"answer\":\"The study uses covalent conjugation between a modified antibody and functionalized liposomes via click chemistry, forming a targeted nanocarrier. It delivers higher doxorubicin levels to PD-L1-overexpressing SKOV-3 cells with reduced systemic toxicity.\"}]","The Development of Antibody-Functionalized Liposomes via Click Chemistry - for Precision Targeting of PD-L1-Positive Ovarian Cancer | PDF",1790055384,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc0863d36e41d8ff3ed60a020a154882.webp",983,1296,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1100f4bfce72722095bbbe5c366811f.webp",982,1295,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b7dd4b64624a6ce39f34e61aff3b7a7.webp",981,1293,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c86e48618f0fe29fbd0fa9e7c6c67f3.webp",980,1292]